Repeated Intrathecal Injections of Radioimmunoconjugates for CNS Tumors
Author Information
Author(s): JT Kemshead, K Hopkins, B Pizer, V Papanastassiou, H Coakham, J Bullimore, C Chandler
Primary Institution: University of Bristol
Hypothesis
Can repeated intrathecal injections of 131I-labelled monoclonal antibodies improve treatment outcomes for central nervous system malignancies?
Conclusion
The study suggests that repeated administration of 131I-MAb can increase the therapeutic index without causing significant toxicity.
Supporting Evidence
- Patients received between 2026 and 2959 MBq of 131I-MAbs as their initial injection.
- Up to 5920 MBq of 131I-MAb was administered without significant toxicity.
- Pharmacokinetic studies showed that the clearance of the radioimmunoconjugate from the CSF remained constant.
Takeaway
Doctors gave medicine directly into the spine of kids with brain tumors to help them get better, and it worked without making them sick.
Methodology
Eight patients received repeated intrathecal injections of 131I-MAb, and pharmacokinetic data were collected to assess clearance from cerebrospinal fluid and blood.
Limitations
The small sample size limits the generalizability of the findings.
Participant Demographics
Five of the eight patients were children, with various diagnoses including primitive neuroectodermal tumors and carcinomatous meningitis.
Want to read the original?
Access the complete publication on the publisher's website